These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Clinical management of adrenocortical carcinoma. Fassnacht M; Allolio B Best Pract Res Clin Endocrinol Metab; 2009 Apr; 23(2):273-89. PubMed ID: 19500769 [TBL] [Abstract][Full Text] [Related]
4. European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Fassnacht M; Dekkers OM; Else T; Baudin E; Berruti A; de Krijger R; Haak HR; Mihai R; Assie G; Terzolo M Eur J Endocrinol; 2018 Oct; 179(4):G1-G46. PubMed ID: 30299884 [TBL] [Abstract][Full Text] [Related]
5. Update in adrenocortical carcinoma. Fassnacht M; Kroiss M; Allolio B J Clin Endocrinol Metab; 2013 Dec; 98(12):4551-64. PubMed ID: 24081734 [TBL] [Abstract][Full Text] [Related]
6. Current and emerging therapies for adrenocortical carcinoma--review. Przytulska J; Rogala N; Bednarek-Tupikowska G Adv Clin Exp Med; 2015; 24(2):185-93. PubMed ID: 25931348 [TBL] [Abstract][Full Text] [Related]
11. What is the best approach to an apparently nonmetastatic adrenocortical carcinoma? Fassnacht M; Allolio B Clin Endocrinol (Oxf); 2010 Nov; 73(5):561-5. PubMed ID: 20738315 [TBL] [Abstract][Full Text] [Related]
12. Adrenocortical carcinoma -- improving patient care by establishing new structures. Koschker AC; Fassnacht M; Hahner S; Weismann D; Allolio B Exp Clin Endocrinol Diabetes; 2006 Feb; 114(2):45-51. PubMed ID: 16570232 [TBL] [Abstract][Full Text] [Related]
13. Approach to the patient with adrenocortical carcinoma. Lacroix A J Clin Endocrinol Metab; 2010 Nov; 95(11):4812-22. PubMed ID: 21051577 [TBL] [Abstract][Full Text] [Related]
14. Future directions in the diagnosis and medical treatment of adrenocortical carcinoma. Creemers SG; Hofland LJ; Korpershoek E; Franssen GJ; van Kemenade FJ; de Herder WW; Feelders RA Endocr Relat Cancer; 2016 Jan; 23(1):R43-69. PubMed ID: 26475053 [TBL] [Abstract][Full Text] [Related]
18. Etoposide, doxorubicin and cisplatin plus mitotane in the treatment of advanced adrenocortical carcinoma: a large prospective phase II trial. Berruti A; Terzolo M; Sperone P; Pia A; Della Casa S; Gross DJ; Carnaghi C; Casali P; Porpiglia F; Mantero F; Reimondo G; Angeli A; Dogliotti L Endocr Relat Cancer; 2005 Sep; 12(3):657-66. PubMed ID: 16172198 [TBL] [Abstract][Full Text] [Related]
19. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer. Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725 [TBL] [Abstract][Full Text] [Related]